Марк Дингман - Ваш мозг. Что нейронаука знает о мозге и его причудах

17.Там же.

18.B.H. Bewernick, S. Kayser, V. Sturm, and T.E. Schlaepfer, “LongTerm Effects of Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant Depression: Evidence for Sustained Efficacy,” Neuropsychopharmacology 37, no. 9 (August 2012): 1975–1985.

19.J.L. Price and W.C. Drevets, “Neural Circuits Underlying the Pathophysiology of Mood Disorders,” Trends in Cognitive Sciences 16, no. 1 (January 2012): 61–71.

20.G.M. Cooney, K. Dwan, C.A. Greig, D.A. Lawlor, J. Rimer, ER. Waugh, M. McMurdo, and G.E. Mead, “Exercise for Depression,” The Cochrane Database of Systematic Reviews 12, no. 9 (September 2013): CD004366.

21Цит. по: F. Lopez-Munoz and C. Alamo, “Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today,” Current Pharmaceutical Design 15 (2009): 1563–1586.

22.E. Shorter, A History of Psychiatry: From the Era of the Asylum to the Age of Prozac (New York: John Wiley & Sons, Inc., 1997).

23.National Center for Health Statistics, “Health, United States, 2010: With Special Feature on Death and Dying,” 2011 Feb. Report, 2011.

24.P.D. Kramer, Listening to Prozac: A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self (New York: Penguin Books, 1993).

25.R. Invernizzi, C. Velasco, M. Bramante, A. Longo, and R. Samanin, “Effect of 5-HT1A Receptor Antagonists on Citalopram-Induced Increase in Extracellular Serotonin in the Frontal Cortex, Striatum and Dorsal Hippocampus,” Neuropharmacology 36, no. 4–5 (1997): 467–473.

26.G.R. Heninger, P.L. Delgado, and D.S. Charney, “The Revised Monoamine Theory of Depression: A Modulatory Role for Monoamines, Based on New Findings from Monoamine Depletion Experiments in Humans,” Pharmacopsychiatry 29, no. 1 (1996): 2-11.

27.I. Kirsch, B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore, and B.T. Johnson, “Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration,” PLoS Medicine 5, no. 2 (2008): e4. Важно отметить, что данная тема неоднозначна и работа авторов была во многом раскритикована. Результаты исследования были опубликованы в 2008 г., и впоследствии появились свидетельства как в поддержку, так и в опровержение полученных в его ходе результатов. Даже в тех исследованиях, которые подтверждают эффективность антидепрессантов, уточняется, что их воздействие на пациента очень ограничено.

28X. Wang, L. Zhang, Y. Lei, X. Liu, X. Zhou, Y. Liu, M. Wang, et al., “Meta-Analysis of Infectious Agents and Depression,” Scientific Reports 4 (2014): 4530.

29.M. Lucas, F. Mirzaei, A. Pan, O.I. Okereke, W.C. Willett, E.J. O’Reilly, K. Koenen, and A. Ascherio, “Coffee, Caffeine, and Risk of Depression among Women,” Archives of Internal Medicine 171, no. 17 (September 2011): 1571–1578.

30.H. Hedegaard, S.C. Curtin, and M. Warner, “Suicide Mortality in the United States, 1999–2017,” NCHS Data Brief 330 (November 2018): 1–7.

1.J. Cole, Pride and a Daily Marathon (Massachusetts: The MIT Press, 1991).

2.G. Fritsch and E. Hitzig, “Electric Excitability of the Cerebrum (Uber die elektrische Erregbarkeit des Grosshirns),” Epilepsy & Behavior 15, no. 2 (June 2009): 123–130.

3.M. Omrani, M.T. Kaufman, N.G. Hatsopoulos, and P.D. Cheney, “Perspectives on Classical Controversies about the Motor Cortex,” Journal of Neurophysiology 118, no. 3 (September 2017): 1828–1848.

4.F.A. Azevedo, L.R. Carvalho, L.T. Grinberg, J.M. Farfel, R.E. Fer-retti, R.E. Leite, W Jacob Filho, R. Lent, and S. Herculano-Houzel, “Equal Numbers of Neuronal and Nonneuronal Cells Make the Human Brain an Isometrically Scaled-Up Primate Brain,” Journal of Comparative Neurology 513, no. 5 (April 2009): 532–541.

5.H.C. Cheng, C.M. Ulane, and R.E. Burke, “Clinical Progression in Parkinson Disease and the Neurobiology of Axons,” Annals of Neurology 67, no. 6 (June 2010): 715–725.

6.C.A. Davie, “A Review of Parkinson’s Disease,” British Medical Bulletin 86 (2008): 109–127.

7.J. Costa, N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro, “Caffeine Exposure and the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Observational Studies,” Journal of Alzheimers Disease 20, Suppl. 1 (2010): S221-S238.

8.M.A. Hernan, B. Takkouche, F Caamano-Isorna, and J.J. Gestal-Otero, “A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson’s Disease,” Annals of Neurology 52, no. 3 (September 2002): 276–284.

9.Y. Misu and Y. Goshima, “Is L-dopa an Endogenous Neurotransmitter?” Trends in Pharmacological Sciences 14, no. 4 (April 1993): 119–123.

10.T.A. Newcomer, P.A. Rosenberg, and E. Aizenman, “Iron-Mediated Oxidation of 3,4-Dihydroxyphenylalanine to an Excitotoxin,” Journal of Neurochemistry 64, no. 4 (1995): 1742–1748.

11G. Porras, P. De Deurwaerdere, Q. Li, M. Marti, R. Morgenstern, R. Sohr, E. Bezard, M. Morari, W.G. Meissnera, “L-Dopa-Induced Dyskinesia: Beyond an Excessive Dopamine Tone In the Striatum,” Scientific Reports 4 (2014): 3730.

1.A.L. Diaz, “Do I Know You? A Case Study Of Prosopagnosia (Face Blindness),” The Journal of School Nursing 24, no. 5 (October 2008): 284–289.

2-I. Kennerknecht, T. Grueter, B. Welling, S. Wentzek, J. Horst, S. Edwards, and M. Grueter, “First Report of Prevalence of Non-Syndromic Hereditary Prosopagnosia (HPA),” American Journal of Medical Genetics Part A 140, no. 15 (August 2006): 1617–1622.

3.J.J.S. Barton and S.L. Corrow, “The Problem of Being Bad at Faces,” Neuropsychologia 89 (August 2016): 119–124.

4.M. Tomasello, B. Hare, H. Lehmann, and J. Call, “Reliance on Head Versus Eyes in the Gaze Following of Great Apes and Human Infants: The Cooperative Eye Hypothesis,” Journal of Human Evolution 52, no. 3 (March 2007): 314–320.

5.K. Koch, J. McLean, R. Segev, M.A. Freed, M.J. Berry, II, V. Bala-subramanian, and P. Sterling, “How Much the Eye Tells the Brain,” Current Biology 16, no. 14 (July 2006): 1428–1434.

6.“Facts about Color Blindness,” National Eye Institute, last modified February 2015, https://nei.nih.gov/health/color_blindness/ facts_about.

7.M. Siniscalchi, S. d’Ingeo, S. Fornelli, and A. Quaranta, “Are Dogs Red-Green Colour Blind?” Royal Society Open Science 4, no. 11 (November 2017): 170869.

8.W.C. Gibson, “Pioneers in Localization of Function in the Brain,” Journal of the American Medical Association 180 (June 1962): 944–951.

9.S. Finger, Origins of Neuroscience (New York: Oxford University Press, 1994).

10.J. Zihl, D. von Cramon, and N. Mai, “Selective Disturbance of Movement Vision after Bilateral Brain Damage,” Brain 106, pt. 2 (June 1983): 313–340.

11.J. Zihl and C.A. Heywood, “The Contribution of LM to the Neuroscience of Movement Vision,” Frontiers in Integrative Neuroscience 9 (February 2015): 6.

12.I. Gauthier, P. Skudlarski, J.C. Gore, and A.W Anderson, “Expertise for Cars and Birds Recruits Brain Areas Involved in Face Recognition,” Nature Neuroscience 3, no. 2 (February 2000): 191–197.

13.E.M. Caves, N.C. Brandley, and S. Johnsen, “Visual Acuity and the Evolution of Signals,” Trends in Ecology & Evolution 33, no. 5 (May 2018): 358–372.

14.B.W. Rovner and R.J. Casten, “Activity Loss and Depression in Age-Related Macular Degeneration,” American Journal of Geriatric Psychiatry 10, no. 3 (May-June 2002): 305–310.